Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma

Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma

Androgen Receptor (AR) signaling is a critical driver of hormone-dependent prostate cancer and has also been proposed to have biological activity in female hormone-dependent cancers, including type I endometrial carcinoma (EMC). In this study, we evaluated the preclinical efficacy of a third-generat...

Full description

Bibliographic Details
Main Authors: Christopher S. Koivisto, Melodie Parrish, Santosh B. Bonala, Soo Ngoi, Adrian Torres, James Gallagher, Rebekah Sanchez-Hodge, Victor Zeinner, Georges J. Nahhas, Bei Liu, David E. Cohn, Floor J. Backes, Paul J. Goodfellow, Helen M. Chamberlin, Gustavo Leone
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
PTEN
Androgen receptor antagonist
Enzalutamide
Endometrial carcinoma
Preclinical drug evaluation
Mouse model of endometrial cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558620301342

Internet

http://www.sciencedirect.com/science/article/pii/S1476558620301342

Similar Items